Brief: Celyad Oncology Announces Clinical Trial Collaboration With MSD
29/09/2020 06:07
Sept 29 (Reuters) - Celyad Oncology CYAD.BR :
* CELYAD ONCOLOGY ANNOUNCES CLINICAL TRIAL COLLABORATION TO
EVALUATE CYAD-101 WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS
WITH MICROSATELLITE STABLE MCRC
* HAS ENTERED INTO A CLINICAL TRIAL COLLABORATION WITH MSD,
A
TRADENAME OF MERCK & CO., INC., KENILWORTH, NJ., USA, THROUGH A
SUBSIDIARY
* COLLABORATION WITH MSD ADDS AN IMPORTANT DIMENSION TO OUR
CLINICAL PROGRAM FOR CYAD-101 FOR TREATMENT OF MCRC - CEO
* COLLABORATION WITH MSD PROVIDES OPPORTUNITY TO BUILD UPON
ENCOURAGING CLINICAL ACTIVITY REPORTED FROM ONGOING ALLOSHRINK
TRIAL - CEO
Source text for Eikon: ID:nGNX5pYJZL
Further company coverage: CYAD.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))